Detection of XXXX in B cell lymphoproliferative disorders by flow cytometry.

@entity1 @entity706 @entity4910 @entity6444 @entity1073 @entity1068
AIMS: To describe and revise a flow cytometric assay for evaluating @entity4910 overexpression in B cell lymphoproliferative disorders (B-LPDs). METHODS: @entity4910 expression was evaluated in 11 healthy controls and 51 @entity1 with B-LPD by flow cytometry using the 5D4 monoclonal antibody. In 25 cases, experiments were repeated up to four times with mononuclear cells (MNC) fixed in @entity1068 for 1-120 days to evaluate the consistency of @entity4910 expression. Flow cytometry results were compared with fluorescence in situ hybridisation (FISH) for the t(11;14) translocation in 19 @entity1 and with immunohistochemistry (IHC) using the DCS-6 monoclonal antibody in nine @entity1 . RESULTS: A mean fluorescence intensity ratio (MFIR) of 4.8 was defined as the cut off point for positivity based on @entity4910 expression in healthy controls (mean + 3 SD). Ten @entity1 overexpressed @entity4910 by flow cytometry. These included five of eight @entity1 with @entity1073 , four of 19 with @entity6444 , and one with @entity706 . MFIR in the repeat experiments differed less than 25% in 20 of 25 @entity1 and in no cases did it cross the cut off point. There was a good correlation between @entity4910 expression by flow cytometry and FISH for t(11;14) in 15 of 19 @entity1 and six of nine had concordant results with flow cytometry, FISH, and IHC. CONCLUSION: @entity4910 expression remains fairly stable once MNC are fixed in @entity1068 and the flow cytometric assay can be used for the routine screening of B-LPD. Further comparisons between flow cytometry, IHC, and FISH may be needed to ascertain the diagnostic value of the flow cytometric assay.
